地图集(解剖学)
转录组
药物发现
内皮功能障碍
药理学
药品
计算生物学
细胞生物学
化学
生物
解剖
基因
基因表达
内分泌学
生物化学
作者
Chunling Tu,Yu Liu,Damon R. Williams,Joseph C. Wu
标识
DOI:10.1016/j.yjmcc.2022.10.002
摘要
Drug-induced vascular burden is a critical challenge in both pharmaceutical development and clinical setting. In the past two decades, multiple drugs have been withdrawn from the market due to unanticipated adverse vascular complications, such as the increased risk of myocardial infarction and stroke (e.g., sibutramine and valdecoxib), heart valvular disease (e.g., pergolide and dexfenfluramine), and haemorrhagic stroke (e.g., phenylpropanolamine). Furthermore, many cancer drugs, such as anthracyclines, tyrosine kinase inhibitors (TKIs), and proteasome inhibitors, are also well-known to elicit a broad spectrum of vascular dysfunctions [1].
科研通智能强力驱动
Strongly Powered by AbleSci AI